Novavax, Inc. (NVAX) — closed signal from March 13, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 11, 2026.
Predicted vs. what happened
What happened
Reached 47% of the predicted growth at its peak, without hitting the target.
The thesis — published March 13, 2026
Novavax looks like a clearer, more reliable investment now because the business is actually getting healthier instead of just being a temporary vaccine trade. Unexpected profit and a licensing deal with Pfizer mean future revenue may feel more steady, more like regular royalties. Short-term regulation matters, but concrete news creates real near-term reasons the stock could re-rate.
Primary drivers
- Unexpected profit helped show real cash coming in
- Pfizer license could create steady royalty-like revenue
- The stock setup looks healthier and not overheated
- Adds healthcare exposure away from AI-focused names
How it played out
NVAX: target was not reached
Lyra published NVAX at $10.52 on 2026-03-13 with expected growth of 22%. The thesis pointed to an unexpected profit, a Pfizer license that could create steadier royalty-like revenue, a healthier stock setup, and healthcare exposure away from artificial-intelligence-focused names.
Inside the window from 2026-03-13 to 2026-06-11, NVAX peaked at $11.61 on 2026-05-27. That was a 10.3% gain, but it stayed below the $12.83 target. The stock ended at $9.03. The thesis partially played out on price strength, then missed the target and finished below the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.